Biogen and Denali's Parkinson's Drug Fails to Meet Trial Goals
In a disappointing turn, Biogen and Denali Therapeutics have reported that their experimental therapy for Parkinson’s disease did not succeed in a key randomized trial intended to slow the progression of the condition.